LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Broderick SR. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):215–220.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–148.
   PubMed Web of Science ®Google Scholar
• de Vries G, Rosas-Plaza X, van Vugt M, et al. Testicular cancer: determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treat Rev. 2020;88:102054.
   PubMedGoogle Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen C, Kang W, et al. SNHG9 was upregulated in NSCLC and associated with DDP-resistance and poor prognosis of NSCLC patients. Am J Transl Res. 2020;12(8):4456–4466.
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
   PubMed Web of Science ®Google Scholar
• Kong J, Tian H, Zhang F, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019;18(1):175.
   PubMed Web of Science ®Google Scholar
• Hua Q, Xu W, Shen X, et al. Dynamic changes of plasma extracellular vesicle long RNAs during perioperative period of colorectal cancer. Bioengineered. 2021;12(1):3699–3710.
   PubMed Web of Science ®Google Scholar
• Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–848.
   PubMed Web of Science ®Google Scholar
• Chen C, Hou J, Yu S, et al. Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer. Oncol Lett. 2021;21(5):413.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhan Y, Liu S, et al. The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. J Exp Clin Cancer Res. 2018;37(1):226.
   PubMed Web of Science ®Google Scholar
• Chi Y, Wang JD, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.
   PubMed Web of Science ®Google Scholar
• Deng Q, Fang Q, Xie B, et al. Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer. Aging (Albany NY). 2020;12(9):8001–8015.
   PubMedGoogle Scholar
• Wang L, Ma L, Xu F, et al. Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 2018;9(7):761–768.
   PubMed Web of Science ®Google Scholar
• Wang X, Qi G, Zhang J, et al. Knockdown of long noncoding RNA small nucleolar RNA host gene 12 inhibits cell growth and induces apoptosis by upregulating miR-138 in nonsmall cell lung cancer. DNA Cell Biol. 2017;36(11):892–900.
   PubMed Web of Science ®Google Scholar
• Zhou B, Li L, Li Y, et al. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother. 2018;106:850–857.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wei Y, Yan Z, et al. The characteristic landscape of lncRNAs classified by RBP-lncRNA interactions across 10 cancers. Mol Biosyst. 2017;13(6):1142–1151.
   PubMedGoogle Scholar
• Zhang T, Beeharry MK, Wang Z, et al. YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis. Int J Biol Sci. 2021;17(7):1629–1643.
   PubMed Web of Science ®Google Scholar
• Lei W, Wang ZL, Feng HJ, et al. Long non-coding RNA SNHG12promotes the proliferation and migration of glioma cells by binding to HuR. Int J Oncol. 2018;53(3):1374–1384.
   PubMed Web of Science ®Google Scholar
• Tu H, Costa M. XIAP’s profile in human cancer. Biomolecules. 2020;10(11):1493.
   PubMed Web of Science ®Google Scholar
• Zhao WJ, Deng BY, Wang XM, et al. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells. Asian Pac J Cancer Prev. 2015;16(6):2453–2458.
   PubMedGoogle Scholar
• Liu Y, Wu X, Sun Y, et al. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer. J Int Med Res. 2011;39(5):1682–1692.
   PubMed Web of Science ®Google Scholar
• Patil R, Kale AD, Mane DR, et al. Isolation, culture and characterization of primary cell lines of human buccal mucosal fibroblasts: a combination of explant enzamytic technique. J Oral Maxillofac Pathol. 2020;24(1):68–75.
   PubMedGoogle Scholar
• Shan G, Zhou X, Gu J, et al. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/beta-catenin pathway and upregulating PTEN. Cell Oncol (Dordr). 2021;44(1):45–59.
   PubMed Web of Science ®Google Scholar
• Liu T, Chen G, Sun D, et al. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai). 2017;49(9):808–816.
   PubMed Web of Science ®Google Scholar
• Ke SB, Qiu H, Chen JM, et al. ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p. Pathol Res Pract. 2020;216(3):152761.
   PubMed Web of Science ®Google Scholar
• Lin XM, Li S, Zhou C, et al. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. Int J Biochem Cell Biol. 2019;116:105610.
   PubMed Web of Science ®Google Scholar
• Liu L, Chai L, Ran J, et al. BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1/HMGCR module. Carcinogenesis. 2020;41(12):1724–1734.
   PubMed Web of Science ®Google Scholar
• Fu J, Cai H, Wu Y, et al. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 2020;755:144886.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang K, Yuan W, et al. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307–9316.
   PubMed Web of Science ®Google Scholar
• Qin X, Guo H, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20(1):12.
   PubMed Web of Science ®Google Scholar
• Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239:116984.
   PubMed Web of Science ®Google Scholar
• Cheng C, Song D, Wu Y, et al. RAC3 promotes proliferation, migration and invasion via PYCR1/JAK/STAT signaling in bladder cancer. Front Mol Biosci. 2020;7(218). DOI:10.3389/fmolb.2020.00218
   Google Scholar
• Lin Y, Liu T, Cui T, et al. RNAInter in 2020: RNA interactome repository with increased coverage and annotation. Nucleic Acids Res. 2020;48(D1):D189–D97.
   PubMed Web of Science ®Google Scholar
• Yu C, Cheng Z, Cui S, et al. circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D. J Exp Clin Cancer Res. 2020;39(1):55.
   PubMed Web of Science ®Google Scholar
• Deng X, Ruan H, Zhang X, et al. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020;146(6):1700–1716.
   PubMed Web of Science ®Google Scholar
• Lv Q, Dong F, Zhou Y, et al. RNA-binding protein SORBS2 suppresses clear cell renal cell carcinoma metastasis by enhancing MTUS1 mRNA stability. Cell Death Dis. 2020;11(12):1056.
   PubMed Web of Science ®Google Scholar
• Jones-Bolin S. Guidelines for the care and use of laboratory animals in biomedical research. Curr Protoc Pharmacol. 2012;Appendix 4: Appendix 4B.
   PubMedGoogle Scholar
• Li L, Wan K, Xiong L, et al. CircRNA hsa_circ_0087862 acts as an oncogene in non-small cell lung cancer by targeting miR-1253/RAB3D axis. Onco Targets Ther. 2020;13:2873–2886.
   PubMed Web of Science ®Google Scholar
• Lv X, Lian Y, Liu Z, et al. Exosomal long non-coding RNA LINC00662 promotes non-small cell lung cancer progression by miR-320d/E2F1 axis. Aging (Albany NY). 2021;13(4):6010–6024.
   PubMedGoogle Scholar
• Wang Z, Lin M, He L, et al. Exosomal lncRNA SCIRT/miR-665 transferring promotes lung cancer cell metastasis through the inhibition of HEYL. J Oncol. 2021;2021:9813773.
   PubMed Web of Science ®Google Scholar
• Gao L, Tian Q, Wu T, et al. Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis. J Transl Med. 2021;19(1):37.
   PubMed Web of Science ®Google Scholar
• Tao Y, Tang Y, Yang Z, et al. Exploration of serum exosomal LncRNA TBILA and AGAP2-AS1 as promising biomarkers for diagnosis of non-small cell lung cancer. Int J Biol Sci. 2020;16(3):471–482.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu H. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients. J Clin Lab Anal. 2020;34(6):e23237.
   PubMed Web of Science ®Google Scholar
• Wang P, Chen D, Ma H, et al. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 2017;8(48):84086–84101.
   PubMedGoogle Scholar
• Xie FW, Liu JC. LncRNA SNHG12 regulates the miR-101-3p/CUL4B axis to mediate the proliferation, migration and invasion of non-small cell lung cancer. Kaohsiung J Med Sci. 2021;37(8):664–674.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng G, Huang Z, et al. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 2020;11(7):515.
   PubMed Web of Science ®Google Scholar
• Lu C, Wei Y, Wang X, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19(1):28.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhang X, Fu X, et al. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. J Cell Biochem. 2019;120(8):12628–12637.
   PubMed Web of Science ®Google Scholar
• Jonas K, Calin GA, Pichler M. RNA-binding proteins as important regulators of long non-coding RNAs in cancer. Int J Mol Sci. 2020;21(8):2969.
   PubMed Web of Science ®Google Scholar
• Zhang T, Beeharry MK, Zheng Y, et al. Long noncoding RNA SNHG12 promotes gastric cancer proliferation by binding to HuR and stabilizing YWHAZ expression through the AKT/GSK-3beta pathway. Front Oncol. 2021;11:645832.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lian T, Fan W, et al. Long-Noncoding RNA CASC9 promotes progression of non-small cell lung cancer by promoting the expression of CDC6 through binding to HuR. Cancer Manag Res. 2020;12:9033–9043.
   PubMed Web of Science ®Google Scholar
• Qin H, Ni H, Liu Y, et al. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020;13(1):90.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546.
   PubMed Web of Science ®Google Scholar
• Wang N, Song L, Xu Y, et al. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine. 2019;47:65–77.
   PubMed Web of Science ®Google Scholar
• Hu Z, Cai M, Zhang Y, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle. 2020;19(2):193–206.
   PubMed Web of Science ®Google Scholar
• Wu H, Mu X, Liu L, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020;11(9):801.
   PubMed Web of Science ®Google Scholar
• Dittmer A, Dittmer J. Carcinoma-associated fibroblasts promote growth of Sox2-expressing breast cancer cells. Cancers (Basel). 2020;12(11):3435.
   PubMed Web of Science ®Google Scholar
• Meng Q, Luo X, Chen J, et al. Unmasking carcinoma-associated fibroblasts: key transformation player within the tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188443.
   PubMed Web of Science ®Google Scholar
• Su S, Chen J, Yao H, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841–56 e16.
   PubMed Web of Science ®Google Scholar
• Wei LY, Lee JJ, Yeh CY, et al. Reciprocal activation of cancer-associated fibroblasts and oral squamous carcinoma cells through CXCL1. Oral Oncol. 2019;88:115–123.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhao C, Xu F, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860–2875.
   PubMed Web of Science ®Google Scholar
• Khoo XH, Paterson IC, Goh BH, et al. Cisplatin-resistance in oral squamous cell carcinoma: regulation by tumor cell-derived extracellular vesicles. Cancers (Basel). 2019;11(8):1166.
   PubMed Web of Science ®Google Scholar
• Tong Y, Yang L, Yu C, et al. Tumor-secreted exosomal lncRNA POU3F3 promotes cisplatin resistance in ESCC by inducing fibroblast differentiation into CAFs. Mol Ther Oncolytics. 2020;18:1–13.
   PubMed Web of Science ®Google Scholar
• Han M, Qian X, Cao H, et al. lncRNA ZNF649-AS1 induces trastuzumab resistance by promoting ATG5 expression and autophagy. Mol Ther. 2020;28(11):2488–2502.
   PubMed Web of Science ®Google Scholar
• Lei Y, Guo W, Chen B, et al. Tumorreleased lncRNA H19 promotes gefitinib resistance via packaging into exosomes in nonsmall cell lung cancer. Oncol Rep. 2018;40(6):3438–3446.
   PubMed Web of Science ®Google Scholar
• Ren J, Ding L, Zhang D, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932–3948.
   PubMed Web of Science ®Google Scholar
• Shen JG, Xu SN, Yin LG. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp. Gen Physiol Biophys. 2020;39(5):481–489.
   PubMed Web of Science ®Google Scholar
• Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3(7):506–528.
   PubMed Web of Science ®Google Scholar
• Grammatikakis I, Abdelmohsen K, Gorospe M. Posttranslational control of HuR function. Wiley Interdiscip Rev RNA. 2017;8(1). DOI:10.1002/wrna.1372
   Web of Science ®Google Scholar
• Li T, Mo X, Fu L, et al. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget. 2016;7(8):8601–8612.
   PubMedGoogle Scholar
• Kang D, Lee Y, Lee JS. RNA-binding proteins in cancer: functional and therapeutic perspectives. Cancers (Basel). 2020;12(9):2699.
   PubMed Web of Science ®Google Scholar
• Nyati KK, Zaman MM, Sharma P, et al. Arid5a, an RNA-binding protein in immune regulation: RNA stability, inflammation, and autoimmunity. Trends Immunol. 2020;41(3):255–268.
   PubMed Web of Science ®Google Scholar
• Lucchesi C, Sheikh MS, Huang Y. Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2. Oncogene. 2016;35(20):2565–2573.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zou T, Rao JN, et al. Stabilization of XIAP mRNA through the RNA binding protein HuR regulated by cellular polyamines. Nucleic Acids Res. 2009;37(22):7623–7637.
   PubMed Web of Science ®Google Scholar
• Shang MJ, Hong DF, Hu ZM, et al. Cisplatin induces apoptosis of hepatocellular carcinoma LM3 cells via down-regulation of XIAP. Eur Rev Med Pharmacol Sci. 2018;22(2):382–387.
   PubMed Web of Science ®Google Scholar
• Chen Z, Qi T, Qin XP, et al. Long noncoding RNA SNHG12 promotes prostate tumor occurrence and progression via AKT regulation. Biomed Res Int. 2020;2020:8812923.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhou W, Du SQ, et al. Overexpression of SNHG12 regulates the viability and invasion of renal cell carcinoma cells through modulation of HIF1alpha. Cancer Cell Int. 2019;19:128.
   PubMed Web of Science ®Google Scholar
• Tamang S, Acharya V, Roy D, et al. SNHG12: an LncRNA as a potential therapeutic target and biomarker for human cancer. Front Oncol. 2019;9:901.
   PubMed Web of Science ®Google Scholar